Optimising stroke prevention in non-valvular atrial fibrillation (Q28200609)

Europe PubMed Central

title

Optimising stroke prevention in non-valvular atrial fibrillation (English)

0 references

0 references

Stéphane Ederhy

1

1 reference

ORCID Public Data File 2021

author name string

Ariel Cohen

series ordinal

2

0 references

language of work or name

English

0 references

publication date

October 2006

0 references

published in

Expert Opinion on Pharmacotherapy

0 references

volume

7

0 references

issue

15

0 references

page(s)

2079-94

0 references

cites work

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1517/14656566.7.15.2079

Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14656566.7.15.2079

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14656566.7.15.2079

Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14656566.7.15.2079

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/14656566.7.15.2079

Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The fiamingham Study

20 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Impact of atrial fibrillation on mortality, stroke, and medical costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Impact of atrial fibrillation on the risk of death: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Echocardiographic assessment of the left atrial appendage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Does atrial fibrillation confer a hypercoagulable state?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Validation of Clinical Classification Schemes for Predicting Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Why do patients with atrial fibrillation not receive warfarin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Anticoagulants for atrial fibrillation: why is the treatment rate so low?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Anticoagulation in hospitals and general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

A comparison of rate control and rhythm control in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Atrial fibrillation and congestive heart failure: risk factors, mechanisms, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Circumferential pulmonary-vein ablation for chronic atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Catheter ablation for atrial fibrillation in congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Bleeding complications in patients with atrial fibrillation undergoing cardioversion randomized to transesophageal echocardiographically guided and conventional anticoagulation therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

The safety of low-molecular weight heparins for the prevention of thromboembolic events after cardioversion of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Cardioversion under the guidance of transesophageal echochardiograhy in persistent atrial fibrillation: results with low molecular weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Are there patients with acute ischemic stroke and atrial fibrillation that benefit from low molecular weight heparin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Trials and tribulations of non-inferiority: the ximelagatran experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Ximelagatran--promises and concerns

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Is atrial fibrillation an inflammatory disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481--the Home INR Study (THINRS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079

Which approach to anticoagulation management is best? Illustration of an interactive mathematical model to support informed decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2079